Fig. 5: FUS-CRISPR-mediated telomere disruption enhances the efficacy of CAR-T therapy in vivo.
From: Ultrasound Control of Genomic Regulatory Toolboxes for Cancer Immunotherapy
a Timeline of FUS-CRISPR-mediated telomere disruption experiment in NSG mice. b–d Tumor aggressiveness in the mice in (a) quantified by the total flux of the tumor from BLI measurement (b), the corresponding BLI images (c), and the tumor volume based on caliper measurement (d). e Survival curves of the tumor-bearing mice in (a). f Experimental timeline of FUS-CRISPR combined with CAR-T therapy in NSG mice. g–i Tumor aggressiveness in the mice in (f) quantified by the total flux of the tumor (g), the corresponding BLI images (h), and the caliper-measured tumor volume (i) In (g), P = 1.22 × 10−5. In (i), P = 8.82 × 10−6. j Survival curves of the tumor-bearing mice in (f). Data points represent means; error bands represent s.e.m.; n = 5 mice per group. Two-way ANOVA followed by Sidak’s multiple comparisons test was used in (b, d, g, and i). Log-rank (Mantel-Cox) test was used in (e and j). Source data are provided as a Source Data file. Created in BioRender. Liu, L. (2024) https://BioRender.com/r77l232.
